Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Celgene Corp | 25 |
| 2 | Massachusetts Institute of Technology | 25 |
| 3 | Astex Therapeutics Ltd | 21 |
| 4 | Institut National de la Sante et de la Recherche Medicale INSERM | 20 |
| 5 | Deutsches Krebsforschungszentrum DKFZ | 19 |
| 6 | Brigham and Womens Hospital Inc | 17 |
| 7 | University of Texas System | 15 |
| 8 | University of Southern California USC | 14 |
| 9 | Harvard University | 13 |
| 10 | University of Texas at Austin | 13 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 522 |
| 2 | A61K | Medicinal preparations | 511 |
| 3 | C12N | Microorganisms, enzymes | 205 |
| 4 | C12Q | Measuring/testing involving enzymes | 188 |
| 5 | C07K | Peptides | 164 |
| 6 | G01N | Investigating / analysing materials | 121 |
| 7 | C07D | Heterocyclic compounds | 82 |
| 8 | C07H | Sugars and derivatives | 82 |
| 9 | C12Y | Enzyme nomenclature (EC numbers) | 36 |
| 10 | Y02A | Climate change adaptation | 34 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| PREPARATION OF DECITABINE | 2010 | Dr Reddys Laboratories Inc | 11 |
| Method for producing 2' -deoxy-5-azacytidine (decitabine) | 2011 | Cilag AG | 10 |
| COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME | 2021 | Novartis AG | 7 |
| METHOD OF PRODUCING 2' -DEOXY-5-AZACYTIDINE (DECITABINE) | 2009 | Cilag AG | 7 |
| COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | 2010 | Eisai Inc | 5 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Epigenetics and DNA Methylation | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | James G. Herman | Johns Hopkins University | 4 |
| 2 | Chung S. Yang | Rutgers, The State University of New Jersey | 3 |
| 3 | Gunn Iren Meling | University of Oslo | 3 |
| 4 | Guro E. Lind | Norwegian Cancer Society | 3 |
| 5 | John D. Minna | The University of Texas Southwestern Medical Center | 3 |
| 6 | Adi F. Gazdar | The University of Texas Southwestern Medical Center | 2 |
| 7 | Chang-Lai Hao | Institute of Hematology & Blood Diseases Hospital | 2 |
| 8 | Claudia Arce | Instituto Nacional de Cancerología | 2 |
| 9 | Cármen Jerónimo | Universidade do Porto | 2 |
| 10 | Edward Gabrielson | Johns Hopkins University | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine | 2008 | 948 | HIV Research and Treatment |
| Strategies for reversing drug resistance | 2003 | 357 | Epigenetics and DNA Methylation |
| Mechanisms of metastasis | 2008 | 296 | Cancer Cells and Metastasis |
| Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene | 2001 | 279 | Cancer-related molecular mechanisms research |
| Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes | 2006 | 256 | Epigenetics and DNA Methylation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Decitabine?
Which organizations hold the most patents related to Decitabine?
What are the main patent classification areas for Decitabine-related inventions?
What recent therapeutic applications of Decitabine are covered in patent filings?
What is the current patent activity trend for Decitabine?